Traitomic Secures €20 Million for Non-GE Trait Platform
Traitomic, a biotech spinout from Carlsberg, has raised €20 million in a Series A funding round led by Sofinnova Partners.

Traitomic has secured €20 million in its first external investment as a standalone company. The Series A funding round was led by Sofinnova Partners with participation from EIFO, Footprint Firm, Nordic Foodtech VC, PSV Hafnium, and SVG Ventures.
This capital injection marks a key step for the Copenhagen-based biotechnology firm following its spinout from Carlsberg. The funding is earmarked for accelerating international growth and enhancing commercial capabilities.
Platform and Market Traction
Traitomic's core technology is the FIND-IT platform. It identifies specific genetic variants within conventionally bred populations without using gene editing. This approach allows for rapid trait development while maintaining broad regulatory and commercial acceptance.
The company has already delivered 116 traits to 47 customers across 32 different organisms. Its customer base spans multiple sectors.
These projects demonstrate the platform's versatility. It bridges a gap often described as slow, fragmented, and difficult to scale between biological discovery and commercial trait delivery.
Strategic Focus on International Growth and Integration
The new funding will propel Traitomic's international expansion. A key strategic focus is broadening its integrated service offering. The company plans to work more closely with customers from the initial identification of a biological or commercial challenge straight through to the delivery of market-ready traits.
This integrated model is designed to deepen collaboration and accelerate impact. The goal is to capitalize on significant opportunities across the global food, agriculture, and biosolutions markets. Strengthening both scientific and commercial teams will support this expansion.
Industry Impact and Future Outlook
Traitomic develops market-ready, non-genetically edited traits in both plants and microorganisms. Its work addresses pressing challenges in food security, resource efficiency, and sustainability. The technology originated at the Carlsberg Research Laboratory, initially for barley improvement, but now enables advances far beyond its original application.
Anders Røed, Executive Vice President for Group Strategy and Commercial at Carlsberg, stated that Traitomic is an excellent example of how fundamental research can create value beyond its initial field. He expressed pride in the team's achievements and excitement for its next phase of international growth.
CEO and co-founder Gustav Hambraeus said the investment marks the beginning of Traitomic's next chapter. He noted that customers across the food value chain are seeking faster routes from biological insight to commercial impact. The support from new investors will enable deeper customer collaboration.
Michael Krel, a partner at Sofinnova Partners, highlighted Traitomic's rare ability to develop commercially relevant traits across a broad range of organisms and applications. Combined with strong customer traction, he believes this creates a compelling foundation for future growth. Sofinnova sees Traitomic as well-positioned to become a leading partner for trait development across its target sectors.
The company will continue to expand its integrated offering to deliver market-ready traits across food, agriculture, and industrial biotech through closer customer collaboration from challenge identification.





